Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₩ 19300
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Onconic Therapeutics, Inc. is a biopharmaceutical company. It engages in the research and development of new drugs in the field of acid-related diseases and anti cancer. The company was founded on May 7, 2020 and is headquartered in Seoul, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Data is available to registered users only
Target Price
The average target price of 476060.KQ is 12500 and suggests 36% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation
Data is available to registered users only
Buy
Sell